Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexa Childs

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
British Journal of Cancer|September 16, 2021
Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK auditAlexa Childs, Nekisa Zakeri, Yuk Ting Ma, et al.
Cancers|July 13, 2024
A Prospective Observational Cohort Study for Newly Diagnosed Osteosarcoma Patients in the UK: ICONIC Study Initial ResultsAlexa Childs, Craig Gerrand, Bernadette Brennan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)Andreas Wicki, Nicholas Brown, Alexandros Xyrafas, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
British Journal of Cancer|September 16, 2021
Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK auditAlexa Childs, Nekisa Zakeri, Yuk Ting Ma, et al.
Cancers|July 13, 2024
A Prospective Observational Cohort Study for Newly Diagnosed Osteosarcoma Patients in the UK: ICONIC Study Initial ResultsAlexa Childs, Craig Gerrand, Bernadette Brennan, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)Andreas Wicki, Nicholas Brown, Alexandros Xyrafas, et al.
Pageof 2